Advaxis, Inc.

Advaxis receives approvals to commence study of Listeria vaccine for cervical cancer

Published in Managed Care Business Week, April 4th, 2006

Advaxis, Inc., (ADXS) has received the approval of the Ministry of Health of Mexico and, subject to the approval of the ethical committee of Hadassah Hospital, the approval of the Ministry of Health of Israel to commence in those countries a phase I/II trial study of Lovaxin C, a Listeria-based vaccine, directed towards the treatment of cervical cancer.

These approvals follow a recently announced approval by the Serbian Agency for Drugs and Medicinal Devices to conduct a study at the Institute for Oncology and Radiology in Belgrade.

The study is the first-in-man study by Advaxis in its proposed development of a new class of cancer therapy using...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Managed Care Business Week

Source: Managed Care Business Week (2006-04-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry